Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.61 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.53 |
| ▸ | DAO | P14920 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 4/20 | 0.47 |
| ▸ | PDE2A | O00408 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | MPL | P40238 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4496729 | 0.98 | IDO1 (0.64) | IDO1TAAR1DAOMAOBPDE2A | |
| SCHEMBL23891924 | 0.87 | IDO1 (0.56) | IDO1TAAR1DAOMAOBPDE2A | |
| SCHEMBL7868348 | 0.86 | TAAR1 (0.51) | IDO1TAAR1DAOMAOB | |
| SCHEMBL507107 | 0.86 | IDO1 (0.62) | IDO1TAAR1DAOMAOBPDE2A | |
| SCHEMBL20472553 | 0.84 | IDO1 (0.61) | IDO1TAAR1DAOMAOBPDE2A | |
| Hydrochloric Acid SCHEMBL30525006 | 0.84 | IDO1 (0.66) | IDO1TAAR1DAOMAOBPDE2A | |
| SCHEMBL3632101 | 0.82 | IDO1 (0.54) | IDO1TAAR1DAOPDE2ASLC6A4 | |
| SCHEMBL2600180 | 0.82 | IDO1 (0.54) | IDO1TAAR1DAOPDE2ASLC6A4 | |
| SCHEMBL18097379 | 0.82 | IDO1 (0.54) | IDO1TAAR1DAOPDE2ASLC6A4 | |
| SCHEMBL5440588 | 0.82 | IDO1 (0.54) | IDO1TAAR1DAOPDE2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10952435-B2 | Pyridine-2-carboxamides as nematocides | SYNGENTA PARTICIPATIONS AG (CH) | 2021-03-23 | — | — | US | disclosed |
| US-10654834-B2 | Non-systemic TGR5 agonists | Venenum Biodesign, LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190330191-A1 | NOVEL NON-SYSTEMIC TGR5 AGONISTS | Venenum Biodesign, LLC (US) | 2019-10-31 | — | — | US | disclosed |
| EP-3362446-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A MORPHOLINE MOIETY | Indivior UK Limited (GB) | 2018-08-22 | — | — | EP | disclosed |
| EP-3022181-B1 | PYRIDINE-2-CARBOXAMIDES AS NEMATOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2018-03-07 | — | — | EP | disclosed |
| EP-3221298-A1 | 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINES AS MODULATORS OF GPR139 | Takeda Pharmaceutical Company Limited (JP) | 2017-09-27 | — | — | EP | disclosed |
| WO-2017064488-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A MORPHOLINE MOIETY | INDIVIOR UK LIMITED (GB) | 2017-04-20 | — | — | WO | disclosed |
| US-20160165887-A1 | PYRIDINE-2-CARBOXAMIDES AS NEMATOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-06-16 | — | — | US | disclosed |
| WO-2016081736-A1 | 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINES AS MODULATORS OF GPR139 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-05-26 | — | — | WO | disclosed |
| EP-3022181-A1 | PYRIDINE-2-CARBOXAMIDES AS NEMATOCIDES | Syngenta Participations AG (CH) | 2016-05-25 | — | — | EP | disclosed |
| US-8193183-B2 | 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists | AVENTIS PHARMACEUTICALS INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-7517889-B2 | 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517889-B2 | 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20070265291-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070265291-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070244131-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244131-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | BAYLISS TRACY | 2007-06-14 | — | — | US | disclosed |
| EP-1687306-A1 | BICYCLIC PYRIMIDIN-4-(3H)-ONES AND ANALOGUES AND DERIVATIVES THEREOF WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) | MERCK SHARP & DOHME LTD. (GB) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005049613-A1 | BICYCLIC PYRIMIDIN-4-(3H)-ONES AND ANALOGUES AND DERIVATIVES THEREOF WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) | MERCK SHARP & DOHME LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330191-A1 | NOVEL NON-SYSTEMIC TGR5 AGONISTS | GPR119, FFAR1, FFAR3 | IDO1 1914/4885TAAR1 121/4885DAO 1453/4885 |
| US-10654834-B2 | Non-systemic TGR5 agonists | GPR119, SSTR5, FFAR3 | IDO1 1577/4885TAAR1 132/4885DAO 1394/4885 |
| US-20160165887-A1 | PYRIDINE-2-CARBOXAMIDES AS NEMATOCIDES | TUBA3C, CYCS, ACHE | IDO1 253/4885TAAR1 1176/4885DAO 2630/4885 |
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | TRPV1, TRPV2, TRPV4 | IDO1 2203/4885TAAR1 418/4885DAO 4029/4885 |
| US-20070244131-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | CYSLTR2, PTGER2, CYSLTR1 | IDO1 172/4885TAAR1 786/4885DAO 3596/4885 |
| US-20070265291-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | CYSLTR2, PTGER2, CYSLTR1 | IDO1 172/4885TAAR1 786/4885DAO 3596/4885 |
| US-10952435-B2 | Pyridine-2-carboxamides as nematocides | TUBA3C, CYCS, ACHE | IDO1 253/4885TAAR1 1176/4885DAO 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.